Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,3010€
Last updated
21/10/2024 - 23:22
-1,63%
€10.5M
Sales in 2023
+42%
Sales growth in 2023
excluding exchange rates
+52%
PPU growth in 2023
excluding exchange rates
Events and Presentations
Financial Results
GovernanceÂ
Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales
Voting Rights Information – September 2024
Voting Rights Information – August 2024
Voting Rights Information – July 2024
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
News
Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance
Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales Â
Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with CellvizioÂ
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 64,702,127
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISINÂ : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
Guillaume Cuvillier
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France
• Exco Socodec, represented by Monsieur Olivier Gallezot, 51, Avenue Françoise Giroud, Parc Valmy, 21066 Dijon
LIQUIDITY CONTRACT
Gilbert Dupont